Roche

Data show combination of protease inhibitor plus Fuzeon most effective in viral suppression in HIV

Published in AIDS Weekly and Law, January 19th, 2006

New clinical data presented at the 45th annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) demonstrate that the highest rates of viral suppression with an experimental boosted protease inhibitor (PI), TMC-114/ritonavir, were achieved in HIV patients who initiated the drug in combination with Fuzeon (enfuvirtide).

The data provide fresh evidence further supporting a new therapeutic strategy for treatment-experienced HIV patients, which was recently recommended in updated antiretroviral treatment guidelines from the U.S. Department of Health and Human Services (DHHS). Fuzeon, codeveloped by Roche and Trimeris (TRMS), is the first and only...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly and Law

Source: AIDS Weekly and Law (2006-01-19)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry